Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Jul 31;13(7):1312-1314.
doi: 10.21037/tau-23-663. Epub 2024 Jul 16.

Stereotactic ablative radiotherapy: a game-changer in primary renal cancer therapy

Francesco Mosè Castronovo  1 , Thomas Zilli  1   2   3 , Antonio Angrisani  1 , Davide Giovanni Bosetti  1
Affiliations
Editorial

Stereotactic ablative radiotherapy: a game-changer in primary renal cancer therapy

Francesco Mosè Castronovo et al. Transl Androl Urol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-23-663/coif). The authors have no conflicts of interest to declare.

Comment on

References

    1. Bukavina L, Bensalah K, Bray F, et al. Epidemiology of Renal Cell Carcinoma: 2022 Update. Eur Urol 2022;82:529-42. 10.1016/j.eururo.2022.08.019 - DOI - PubMed
    1. Hannan R, McLaughlin MF, Pop LM, et al. Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer. Eur Urol 2023;84:275-86. 10.1016/j.eururo.2023.02.016 - DOI - PMC - PubMed
    1. Siva S, Ali M, Correa RJM, et al. 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney). Lancet Oncol 2022;23:1508-16. 10.1016/S1470-2045(22)00656-8 - DOI - PubMed
    1. Siva S, Chesson B, Bressel M, et al. TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II. BMC Cancer 2018;18:1030. 10.1186/s12885-018-4916-2 - DOI - PMC - PubMed
    1. Siva S, Bressel M, Sidhom M, et al. TROG 15.03/ANZUP International Multicenter Phase II Trial of Focal Ablative STereotactic RAdiotherapy for Cancers of the Kidney (FASTRACK II). Int J Radiat Oncol Biol Phys 2023. doi: .10.1016/j.ijrobp.2023.06.208 - DOI

LinkOut - more resources